SASLT guidelines: Update in treatment of Hepatitis C virus infection
Abdullah S Alghamdi, Mohammed Alghamdi, Faisal M Sanai and 7 more
The Saudi Journal of Gastroenterology · 2016
doi:10.4103/1319-3767.188067 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
The Saudi Association for the Study of Liver Diseases and Transplantation (SASLT) formed a task force to evaluate the current methods of optimal management of the Hepatitis C virus (HCV) infection in Saudi Arabia. All members of this committee are hepatologists. The first step was to undertake a broad literature search of the published literature on every aspect of HCV management. All available literature on the topic was critically examined, and the available evidence was then classified according to its importance. The contents of the resulting document, including the recommendations contained in it, have been discussed in detail and agreed upon by the members of the SASLT task force. Subsequently, and after review by the board of directors, the guidelines were approved and endorsed by SASLT. All recommendations in these guidelines are based on the best available evidence, and tailored to patients treated in Saudi Arabia. They are graded on the basis of evidence. The purpose of these guidelines is to improve HCV patient care in the Kingdom and to promote and improve the multidisciplinary care required in the treatment of these patients. They are intended for use by physicians and offer the recommended approaches to treatment of HCV with the new direct-acting antiviral treatment. Grading of recommendations based on quality of evidence Grade A: Recommendation based on at least one high quality randomized controlled trial or at least one high quality meta-analysis of methodologically sound randomized controlled trials. Grade B: Recommendation based on high quality case-control or cohort studies or a high quality systematic review. Grade C: Recommendation based on nonanalytic studies (case reports or case series). Grade D: Recommendation based on expert opinion only. The strength of each recommendation can be divided into: Level 1: strong, based on quality of evidence, patient outcome, and cost Level 2: weak, with variability in values, preferences, and less certainty. Goals of these guidelines These are as follows: To complement the previous SASLT guidelines in the management of hepatitis C in Saudi Arabia To provide an evidence-based approach for the management of HCV-infected patients To eradicate HCV infection. Succeeding in this aim would result in a decrease in liver-related complications, deaths, the need for liver transplantations, and hepatocellular carcinoma rate. INTRODUCTION Hepatitis C virus (HCV) has been reported to be on the decline over the past decade, although it remains a major public health concern in Saudi Arabia. Its prevalence in Saudi Arabia is generally uncertain because most studies were conducted more than 10 years ago. However, data from blood donor screening centers indicates prevalence rates of 0.4–1.1%.[1] The premarital screening data in a predominantly young population from a survey among 74662 individuals conducted in the period between January and May 2008, the results of which were published by the Ministry of Health, showed an HCV prevalence of only 0.33%.[2] Similarly, a community-based study in 16–18 years old Saudi adolescents in 2008 showed a prevalence of HCV at 0.22% in the group.[1] The most prevalent genotype is genotype (GT) 4, followed by GT1. HCV GT4 accounts for 60% of the cases, GT1 for 25.9%, GT2 for 4.3%, GT3 for 2.9%, and GT5/GT6 for 0.3%. 6.3% of the cases were of mixed genotypes, predominantly between GT1 and GT4.[3] The most common subtypes of GT4 are 4a (48%) and 4d (39%), followed by subtypes 4n (6%) and others (6%).[4] Up to 63% of Saudi patients have minimal to moderate (Metavir, F0–2) histological disease.[5] DIAGNOSIS OF HCV Detection of the anti-HCV antibody is the method used for screening of HCV infection. Enzyme immunoassays (EIAs) is the commonly used test, with a specificity of >99% in the detection of anti-HCV.[6] EIA can detect HCV antibodies as early as 6–8 weeks after exposure.[7] Overall, HCV antibody tests have a strong positive predictive value for exposure to the HCV. If anti-HCV antibodies are detected, HCV RNA should then be determined by a sensitive molecular method such as polymerase chain reaction (PCR), transcription mediated amplification (TMA), or branched DNA (b-DNA) with a lower limit of detection of <15 international units (IU)/ml. All HCV nucleic acid molecular tests have the capacity to detect the presence of the virus and to measure the amount of the virus present in the blood (the HCV viral load). Viral RNA testing is also indicated when there is a clinical suspicion of HCV, transaminase levels are high, and antibody testing is negative.[8] HCV genotype and subtype can be determined via various methods, including direct sequence analysis, reverse hybridization, and genotype-specific real-time PCR.[9] Genotyping is useful in epidemiological studies, in selecting therapy, predicting the likelihood of response to the chosen and the optimal of treatment. tests to liver tests are for the of liver These tests be used to to or to the antiviral and to the of such The use of of liver and can be recommended as an to and liver for the of liver in patients with hepatitis have been to patients with or However, have also been to be less in between moderate and is a used to liver The can be and is an in the liver can be is at and is which the The in less and such as in patients with liver of liver are in liver is and of the and a of liver which can be to a of in and in is than the and is more of the studies have the of liver with is a to liver The amount of can be and and is in more than of the patients. However, the of the is by and hepatitis and liver such as in can high it be to in such from to with of for for and for to the histological a study to histological on it was liver and were with in more or was to a value to between and by Liver remains the for the of when with clinical and it is also a of to provide the need to However, is to of HCV infection is based on the detection of anti-HCV antibodies by and HCV RNA by a sensitive molecular method limit of detection a real-time patients with anti-HCV antibodies and in cases of HCV RNA should be a of of HCV genotype and subtype is recommended and should be used to the of and of treatment can be used to liver in patients with hepatitis C is to its such as and The use of of liver and can be recommended as an to and liver for the of liver in patients with hepatitis C Liver is for the and of liver the of and the presence or of is and should be for there is or need to be OF C The of direct-acting antiviral HCV is a RNA virus of a viral positive in a or and by viral and a in which are the of HCV in a amount of has been and which has to improve of HCV of the major used in this have in which or of the HCV are to in have the of HCV and which in have the of virus The of a was a in HCV the for viral and screening anti-HCV for viral the HCV has also been with the of viral The HCV and of the HCV viral and of viral of HCV and of new and from 1: HCV The HCV a and The of and The of and and the viral of the which the positive RNA a The viral RNA polymerase is the of RNA treatment of HCV has also over the years its the first was approved for the treatment of hepatitis The rates of response were and reported to be only for GT1 and for GT2 and were from with the of for GT1 and for GT2 and and then for GT1 and for GT2 and in by the to there has been major in hepatitis C treatment with the of the first These and to the of HCV The and and were indicated only for GT1 HCV be in with and as a with results between and However, the of the treatment the of the and the of were major with the use of these the reported results were to of the in to such as virus and patients. are indicated for the treatment of HCV 1: approved direct-acting of in and new of care for HCV patients. the first the results to more than These are with treatment the of an and an with to HCV in a of including liver and with The available are classified based on the of the of to the of the and of viral the of and and a is to of the and its to HCV the They also the and of viral and polymerase to one of of the RNA polymerase the of the its RNA of a polymerase is polymerase as for HCV resulting in chain after the viral of a polymerase is The of hepatitis C virus treatment The of HCV treatment is to hepatitis C infection. is as when HCV RNA is weeks after treatment from infection in more than of The of are and of and liver as as of complications, such as and the of carcinoma in patients is and is Recommendation The of HCV individuals is as by of HCV is with and liver and for hepatitis C virus with direct for of HCV are indicated in patients with HCV and should be to the with or including with or hepatitis virus All with HCV RNA positive including patients with after liver with such or of to to have HCV at a premarital screening of of HCV are are less than years old or patients or to with HCV patients with a years with to of the major between the HCV and be or by the patient for with should or as HCV with or patients on should the in HCV treatment and the of strong and the concern of and of to concern are the patients at a because most of these have such as or with and on The is also in patients after or for need to be in to the of The first in the blood and with of the to can over or to the The is to and of of these and and to and of the are of The is to liver and and is the most common for to of the most has been the of a for which has been by the of on can be on this it is on a as new and can be HCV and are of the new of has a and is to to via is and in the and in the should be with and with and have with and can be used in patients this individuals with liver is to its by the and exposure to from to of are in patients including and and are with and are required when used in with the and of blood of the and is use of has been to result in of to such it is recommended to the is with and of exposure to are by this is a major need to be in the of
Abstract licence: CC BY-NC-SA
References161
- 14.
39 more references, whose wording the paper’s licence keeps private.
All 161 referencesReads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.